bo yan

Prof. bo yan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
RZRui Zheng
Rui Zheng
KSKuo Shen
Kuo Shen
SLSixin Liang
Sixin Liang
YLYanhong Lyu
Yanhong Lyu
SZSiyan Zhang
Siyan Zhang
BYbo yan
bo yan

4 January 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
SLSixin Liang
Sixin Liang
RZRui Zheng
Rui Zheng
BZBaile Zuo
Baile Zuo
JLJia Li
Jia Li
YWYiyi Wang
Yiyi Wang
BYbo yan
bo yan

15 January 2025 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
PWPengju Wang
Pengju Wang
YWYiyi Wang
Yiyi Wang
XZXiaojuan Zhao
Xiaojuan Zhao
RZRui Zheng
Rui Zheng
YZYiting Zhang
Yiting Zhang
LJLintao Jia
Lintao Jia
The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs employ an intracellular domain (ICD) from the ζ subunit of CD3 as a signaling module, and it is largely unknown how alternative CD3 chains potentially contribute to CAR design. Here, we obtained a series of CAR-T cells against HER2 and mesothelin using a domain comprising a single immunoreceptor tyrosine-based activation motif from different CD3 subunits as the ICD of CARs. While these reconstituted CARs conferred sufficient antigen-specific cytolytic activity on equipped T cells, they elicited low tonic signal, ameliorated the exhaustion and promoted memory differentiation of these cells. Intriguingly, the CD3ε-derived ICD outperformed others in generation of CAR-T cells that produced minimized cytokines. Mechanistically, CD3ε-based CARs displayed a restrained cytomembrane expression on engineered T cells, which was ascribed to endoplasmic reticulum retention mediated by the carboxyl terminal basic residues. The present study demonstrated the applicability of CAR reconstitution using signaling modules from different CD3 subunits, and depicted a novel pattern of CAR expression that reduces cytokine release, thus paving a way for preparation of CAR-T cells displaying improved safety and persistence against diverse tumor antigens.

7 November 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
RZRui Zheng
Rui Zheng
YCYuankun Chen
Yuankun Chen
YZYiting Zhang
Yiting Zhang
SLSixin Liang
Sixin Liang
XZXiaojuan Zhao
Xiaojuan Zhao
BYbo yan
bo yan
Introduction: Chimeric antigen receptors (CARs) can redirect T cells against antigen-expressing tumors, and each component plays an important role in the function and anti-tumor efficacy. It has been reported that using human sequences or a low affinity of CAR single-chain variable fragments (scFvs) in the CAR binding domains is a potential way to enhance the function of CAR-T cells. However, it remains largely unknown how a lower affinity of CARs using humanized scFvs affects the function of CAR-T cells until recently.Methods: We used different humanized anti-HER2 antibodies as the extracellular domain of CARs and further constructed a series of the CAR-T cells with different affinity.Results: We have observed that moderately reducing the affinity of CARs (light chain variable domain (VL)-based CAR-T) could maintain the anti-tumor efficacy, and improved the safety of CAR therapy both in vitro and in vivo compared with high-affinity CAR-T cells. Moreover, T cells expressing the VL domain only antibody exhibited long-lasting tumor elimination capability after multiple challenges in vitro, longer persistence and lower cytokine levels in vivo.Discussion: Our findings provide an alternative option for CAR-T optimization with the potential to widen the use of CAR T cells.

1 January 2025 in Immune Discovery
Verified
Journal Article
Open access
PDF file
YLYitong Li
Yitong Li
BZBaile Zuo
Baile Zuo
YXYating Xing
Yating Xing
RZRui Zhang
Rui Zhang
LJLintao Jia
Lintao Jia
HYHuilong Yin
Huilong Yin
SCIEPublish is an international open-access journal publishing service provider run by SCIE Publishing Limited, dedicated to supporting and inspiring scientists or institutions/societies who aspire to publish high-quality journals.

26 August 2025 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
SLSixin Liang
Sixin Liang
RZRui Zheng
Rui Zheng
BZBaile Zuo
Baile Zuo
JLJia Li
Jia Li
YWYiyi Wang
Yiyi Wang
BYbo yan
bo yan